Interaction of CD99 and its ligand upregulates IL-6 and TNF-α upon T cell activation.

Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

Original Publication: San Francisco, CA : Public Library of Science

12E7 Antigen/*metabolism ; Interleukin-6/*biosynthesis ; T-Lymphocytes/*immunology ; Tumor Necrosis Factor-alpha/*biosynthesis; 12E7 Antigen/genetics ; Antibodies, Monoclonal ; CD3 Complex/antagonists & inhibitors ; Cell Proliferation ; Dendritic Cells/immunology ; HEK293 Cells ; Humans ; Killer Cells, Natural/immunology ; Ligands ; Lymphocyte Activation ; Monocytes/immunology ; Recombinant Fusion Proteins/genetics ; Recombinant Fusion Proteins/metabolism ; T-Lymphocytes/cytology ; Up-Regulation

CD99 has been reported to be involved in T cell regulation. CD99 ligand involvement in the regulation of T cell activation has been postulated. In this study, recombinant CD99 proteins were produced and used as a tool for determining the role of CD99 and its ligand interaction. Recombinant CD99 proteins induced the upregulation of IL-6 and TNF-α expression, but not IFN-γ, in anti-CD3 monoclonal antibody activated T cells. The cytokine alteration was not observed in unstimulated T cells indicating the cytokine upregulation required the signal from T cell activation. The upregulation of IL-6 and TNF-α was, in addition, observed in CD3- mononuclear cell population including monocytes and NK cells. The recombinant CD99 proteins, however, did not affect either CD25, CD69 or MHC class II expression or T cell proliferation, upon T cell activation. The CD99 ligands were demonstrated to be expressed on monocytes, NK cells and dendritic cells, but not on B and T cells. Our results indicated the presence of CD99 ligands on leukocyte surface. Interaction between CD99 and its ligands involves the regulation of cytokine production.
Competing Interests: The authors have declared that no competing interests exist.

Eur J Immunol. 1994 Dec;24(12):3148-54. (PMID: 7528671)
Allergol Int. 2017 Jul;66(3):392-397. (PMID: 28320580)
Immunol Lett. 2000 Jan 10;71(1):33-41. (PMID: 10709783)
Hum Immunol. 1983 Dec;8(4):249-54. (PMID: 6606636)
Genes Cancer. 2012 Sep;3(9-10):535-49. (PMID: 23486730)
Nat Immunol. 2001 Mar;2(3):261-8. (PMID: 11224527)
J Korean Med Sci. 1999 Dec;14(6):600-6. (PMID: 10642936)
J Immunol Res. 2015;2015:156787. (PMID: 26000312)
BMC Res Notes. 2011 Aug 13;4:293. (PMID: 21838920)
Immunol Rev. 2009 May;229(1):307-21. (PMID: 19426230)
Genes (Basel). 2018 Mar 13;9(3):. (PMID: 29534016)
J Cell Commun Signal. 2018 Mar;12(1):55-68. (PMID: 29305692)
Mol Cells. 2004 Oct 31;18(2):186-91. (PMID: 15528994)
Arthritis Res. 2002;4 Suppl 3:S177-82. (PMID: 12110137)
Int J Rheumatol. 2011;2011:721608. (PMID: 21941555)
Nat Rev Immunol. 2013 Apr;13(4):227-42. (PMID: 23470321)
Best Pract Res Clin Rheumatol. 2010 Aug;24(4):463-77. (PMID: 20732645)
Arch Oral Biol. 2013 Jan;58(1):82-93. (PMID: 22795566)
Int Immunol. 1999 May;11(5):777-86. (PMID: 10330283)
J Clin Oncol. 2015 Jun 10;33(17):1974-82. (PMID: 25605845)
J Autoimmun. 2000 Feb;14(1):63-78. (PMID: 10648117)
J Exp Med. 1986 Dec 1;164(6):1988-2005. (PMID: 2946796)
J Biol Chem. 2000 Mar 31;275(13):9230-8. (PMID: 10734060)
Blood. 2009 Jan 8;113(2):347-57. (PMID: 18849489)
EMBO J. 1989 Nov;8(11):3253-9. (PMID: 2479542)
Nat Immunol. 2002 Feb;3(2):143-50. (PMID: 11812991)
J Immunol. 1989 Aug 15;143(4):1123-8. (PMID: 2501389)
Cell Commun Adhes. 2008 Nov;15(4):351-63. (PMID: 18923973)
J Exp Med. 2000 Oct 2;192(7):1027-34. (PMID: 11015443)
Immunol Today. 1994 Jul;15(7):321-31. (PMID: 7522010)
PLoS One. 2016 Dec 9;11(12):e0167215. (PMID: 27936140)
FASEB J. 2002 Dec;16(14):1946-8. (PMID: 12368226)
Blood. 1994 Jan 15;83(2):415-25. (PMID: 7506950)
Cytometry. 1997 Jan 1;27(1):71-6. (PMID: 9000587)
J Immunol. 1988 Mar 15;140(6):1802-7. (PMID: 2894395)
Int J Cancer. 2012 Aug 15;131(4):E382-94. (PMID: 22020966)
Eur J Immunol. 1989 Aug;19(8):1431-6. (PMID: 2789140)
Hybridoma (Larchmt). 2007 Aug;26(4):241-50. (PMID: 17725386)
J Clin Invest. 2015 Sep;125(9):3384-91. (PMID: 26325035)
J Immunol. 1998 Nov 1;161(9):4671-8. (PMID: 9794396)
Virchows Arch. 2009 Nov;455(5):397-411. (PMID: 19841938)
Immune Netw. 2015 Oct;15(5):260-7. (PMID: 26557810)
J Immunol. 1992 Aug 1;149(3):847-54. (PMID: 1634773)
J Lipid Res. 2007 Apr;48(4):751-62. (PMID: 17202130)
Cell Rep. 2018 Oct 9;25(2):339-349.e9. (PMID: 30304675)
Exp Mol Med. 2007 Apr 30;39(2):176-84. (PMID: 17464179)
Cytokine Growth Factor Rev. 2017 Oct;37:57-65. (PMID: 28363692)
Crit Rev Biotechnol. 2016 Dec;36(6):1110-1122. (PMID: 26383226)
J Exp Med. 2015 Jun 29;212(7):1021-41. (PMID: 26101266)
Curr Top Microbiol Immunol. 2006;305:177-94. (PMID: 16724806)
Nat Rev Cancer. 2012 Mar 22;12(4):252-64. (PMID: 22437870)
Am J Pathol. 1998 Dec;153(6):1937-45. (PMID: 9846983)
Cancer Immun. 2013;13:5. (PMID: 23390376)
Thromb Res. 2013 Jan;131(1):78-88. (PMID: 23058466)
J Immunol. 1998 Jul 15;161(2):749-54. (PMID: 9670951)
Eur Cytokine Netw. 1993 Jan-Feb;4(1):7-13. (PMID: 8490106)

0 (12E7 Antigen)
0 (Antibodies, Monoclonal)
0 (CD3 Complex)
0 (CD99 protein, human)
0 (IL6 protein, human)
0 (Interleukin-6)
0 (Ligands)
0 (Recombinant Fusion Proteins)
0 (TNF protein, human)
0 (Tumor Necrosis Factor-alpha)

Date Created: 20190524 Date Completed: 20200129 Latest Revision: 20200309

20250114

PMC6532917

10.1371/journal.pone.0217393

31120992